Qilu Pharmaceutical Co., Ltd was Arbutus Biopharma’s largest product and service line in fiscal 2025, bringing in $10.43M of $12.60M (83%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd | — | $10.67M | $1.36M | $10.43M | ||||||
| Qilu Pharmaceutical Co, Ltd | $26.02M | — | — | — | ||||||
| Alexion | — | — | — | — | ||||||
| Royalties From Sales Of Onpattro | — | $3.61M | $2.56M | $1.67M | ||||||
| Onpattro - Non-Cash Royalty | $7.65M | — | — | — | ||||||
| Onpattro - Cash Royalty | $5.32M | — | — | — | ||||||
| Acuitas Therapeutics, Inc | — | — | — | — | ||||||
| Gritstone Oncology, Inc | — | — | — | — | ||||||
| Gritstone | — | — | — | — | ||||||
| Alnylam Pharmaceuticals, Inc | — | — | — | — | ||||||
| Acrotech Biopharma, Llc | — | — | — | — | ||||||
| Other Milestone & Royalty Payments | — | — | — | $500.00K | ||||||
| Other Milestones & Royalty Payments | $35.00K | — | — | — | ||||||
| Dicerna | — | — | — | — | ||||||
| Total | $39.02M | $14.27M | $3.92M | $12.60M |
Arbutus Biopharma brought in $12.60M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. Arbutus Biopharma regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $3.92M. Qilu Pharmaceutical Co., Ltd was the largest at $10.43M (82.8%), ahead of Royalties From Sales Of Onpattro at $1.67M (13.2%) and Other Milestone & Royalty Payments at $500.00K (4.0%).
Compared with fiscal 2024, Qilu Pharmaceutical Co., Ltd grew 668.9% to $10.43M, while Royalties From Sales Of Onpattro fell 34.9% to $1.67M.
Arbutus Biopharma began breaking out Qilu Pharmaceutical Co., Ltd in fiscal 2023 and Royalties From Sales Of Onpattro in fiscal 2023. Arbutus Biopharma stopped reporting Qilu Pharmaceutical Co, Ltd ($26.02M in fiscal 2022), Onpattro - Non-Cash Royalty ($7.65M in fiscal 2022), Onpattro - Cash Royalty ($5.32M in fiscal 2022) and one other as separate lines.
License was Arbutus Biopharma’s largest product and service line in fiscal 2025, bringing in $10.43M of $11.92M (88%).
| Product and Service | FY 2018 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| License | $26.02M | $10.67M | $2.56M | $10.43M | |||||
| Collaboration & Contracts | — | — | — | — | |||||
| Non-Cash Royalty Revenue | $7.65M | $3.87M | $2.25M | $1.48M | |||||
| Total | $33.67M | $14.53M | $4.81M | $11.92M |
Arbutus Biopharma brought in $11.92M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That is less than the $12.60M it reports by product and service, so these lines do not cover all of its revenue. License was the largest at $10.43M (87.6%), ahead of Non-Cash Royalty Revenue at $1.48M (12.4%).
Compared with fiscal 2024, License grew 307.3% to $10.43M, while Non-Cash Royalty Revenue fell 34.2% to $1.48M.
Quarter Four was Arbutus Biopharma’s largest revenue line in fiscal 2013, bringing in $7.53M of $15.46M (49%).
| Quarterly Reporting | FY 2013 |
|---|---|
| Quarter Four | $7.53M |
| Quarter Three | $2.96M |
| Quarter Two | $2.84M |
| Quarter One | $2.13M |
| Total | $15.46M |
Arbutus Biopharma brought in $15.46M from its four revenue lines in fiscal 2013, the year ended December 31, 2013. Quarter Four was the largest at $7.53M (48.7%), ahead of Quarter Three at $2.96M (19.2%) and Quarter Two at $2.84M (18.4%). The remaining revenue line, Quarter One, brought in $2.13M.
Arbutus Biopharma (ABUS) reports its revenue by product and service and by quarterly reporting. In fiscal 2025, Qilu Pharmaceutical Co., Ltd was its largest product and service line, bringing in $10.43M (82.8% of the total), followed by Royalties From Sales Of Onpattro at $1.67M (13.2%).
Qilu Pharmaceutical Co., Ltd was Arbutus Biopharma's largest product and service line in fiscal 2025, bringing in $10.43M, or 82.8% of the $12.60M total across its three product and service lines.
Quarter Four was Arbutus Biopharma's largest revenue line in fiscal 2013, bringing in $7.53M, or 48.7% of the $15.46M total across its four revenue lines.
License grew faster than Non-Cash Royalty Revenue in fiscal 2025, up 307.3% from $2.56M to $10.43M. Non-Cash Royalty Revenue fell 34.2% to $1.48M.
Every figure comes from Arbutus Biopharma's annual financial filings, as reported. Each line keeps the name Arbutus Biopharma gives it, and years follow its fiscal calendar.
Arbutus Biopharma's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.